STAT+: Lilly shares safety, tolerability data on its next-gen obesity drug
STAT [Unofficial]
June 6, 2026
Eli Lilly presented new safety and tolerability data on retatrutide at the annual meeting of the American Diabetes Association on Saturday.
Discussion in the ATmosphere